Log In
Print
BCIQ
Print
Print this Print this
 

odanacatib (formerly MK-0822)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionCathepsin K inhibitor
Molecular Target Cathepsin K (CTSK)
Mechanism of ActionCathepsin K inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationOsteoporosis
Indication DetailsTreat osteoporosis
Regulatory Designation

Partner

Quest Diagnostics Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today